Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen
|
|
- Cuthbert Parsons
- 8 years ago
- Views:
Transcription
1 VOLUME 22 NUMBER 3 FEBRUARY JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen From the Department of Epidemiology, German Centre for Research on Aging, Heidelberg, Germany; Finnish Cancer Registry; and Department of Public Health, University of Helsinki, Helsinki, Finland. Submitted April 8, 2003; accepted October 15, T.H. was supported in part by the Ma- DaMe project of the Academy of Finland, Helsinki. Authors disclosures of potential conflicts of interest are found at the end of this article. Address reprint requests to Hermann Brenner, MD, MPH, Department of Epidemiology, German Centre for Research on Aging, Bergheimer Str 20, D Heidelberg, Germany; Brenner@dzfa-uni-heidelberg.de by American Society of Clinical Oncology X/04/ /$20.00 DOI: /JCO A B S T R A C T Purpose Breast cancer diagnosed before the age of 50 years has become a common disease in many developed countries. Although average remaining life expectancy in the affected age groups is usually several decades, data regarding survival perspectives beyond 10 to 20 years after diagnosis are sparse. The aim of this study was to assess long-term survival in a large population-based sample of patients diagnosed with breast cancer before age 50 years. Patients and Methods Relative survival within up to 40 years after diagnosis was assessed for cohorts of women diagnosed with breast cancer before age 50 years and notified to the nationwide Finnish Cancer Registry within various time intervals since In addition, up-to-date estimates of 40-year relative survival were obtained by exclusively looking at the survival experience of breast cancer patients in recent years (1993 to 1999) using period analysis, a new method of survival analysis. Results Prognosis of patients diagnosed with breast cancer before age 50 years has considerably improved during the past decades. According to the latest estimates from period analysis, cumulative 40-year relative survival is now approximately 43% for all cancers combined, 57% for localized cancers, and 24% for cancers with regional tumor spread. Nevertheless, patients diagnosed with breast cancer before age 50 years continue to have increased mortality throughout at least four decades after diagnosis. This applies even if breast cancer is diagnosed in a localized stage and in the absence of a second primary breast cancer. Conclusion Despite major improvement in prognosis over time, breast cancer occurring among patients who are younger than 50 years remains a chronic disease that affects prognosis for decades. J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION Breast cancer is the most common cancer among women in developed countries [1], and approximately one of four patients are confronted with this diagnosis before the age of 50 years, in other words, at an age when average remaining life expectancy encompasses several decades. Survival perspectives beyond the usual 5- or 10-year follow-up periods included in most pertinent analyses are therefore of major interest to these patients, their relatives, and clinicians. A few studies have addressed survival rates up to 20 years after diagnosis [2], but data beyond that follow-up interval are sparse. A study from Norway including 458 young breast cancer patients found that an excess breast cancer mortality persisted for at least 40 years after diagnosis [3]. By contrast, mortality was quite similar or even lower among breast cancer patients than in the general population of the same age in the third and fourth decade after diagnosis in studies from New Zealand [4], the Netherlands [5,6], and Finland [7]. However, in most of these studies, numbers of patients for whom long-term follow-up was available were small, and with the exception of the studies from Norway and New Zealand [3,4], specific results for younger breast cancer patients, for whom long-term survival perspectives are of particular concern, have 432
2 Prognosis of Young Patients With Breast Cancer not been reported. Furthermore, previous estimates, which were based on traditional methods of survival analysis, pertained to survival expectations of patients diagnosed several decades ago, and they may therefore be of limited relevance for patients diagnosed today given the major improvement in prognosis of breast cancer that has been achieved within the last few decades [8-12]. In this large population-based study from Finland, we applied a new method of survival analysis to provide up-todate estimates of survival up to 40 years after diagnosis among women diagnosed with breast cancer before the age of 50. PATIENTS AND METHODS Our analysis is based on data from the nationwide Finnish Cancer Registry (population base approximately 5.3 million people), which are among the highest-quality data of any population-based cancer registry in the world. Virtually complete population-based cancer registration has been accomplished since 1953 [13]. Notification of cancer cases to the registry is mandatory by law. Notification comes from many different sources, including hospitals, physicians working outside hospitals, dentists, and pathologic and cytologic laboratories. Copies are also obtained of all death certificates where cancer is mentioned. Mortality follow-up is extremely efficient in Finland because of the existence of personal identification numbers [14]. Using these numbers as the key, the cancer registry files are matched annually with the annual lists of deaths. Matching with the central population registry (a register of all people currently alive and living in Finland) is performed as an additional check on the vital status of patients. By the time of this analysis, follow-up with respect to vital status had been completed until the end of This analysis includes patients diagnosed with breast cancer before age 50 years between 1953 and Patients whose cancer was registered by death certificate or autopsy only (0.15% of registered cases) or whose month of death was unknown (0.2%) were excluded. Forty-year survival curves (overall and according to stage at diagnosis) were first estimated for the cohort of patients diagnosed in 1953 through 1959 and followed over 40 years since then by traditional (cohort-wise) life-table analysis. In addition, 30-, 20-, and 10-year survival curves were derived in the same way for patients diagnosed in 1963 through 1969, 1973 through 1979, and 1983 through 1989, respectively. Next, 40-year survival curves were derived for calendar years 1993 through 1999 by a new method of survival analysis, denoted period analysis [15,16], to obtain more up-to-date estimates of long-term prognosis. The methodologic principle of period analysis, which has been described in detail elsewhere [15,16], is simple. With this approach, the estimates of survival curves are exclusively based on survival experience of patients in some recent period (here, in 1993 through 1999, the most recent period for which data were available). This is achieved by left truncation of observations at the beginning of that period (here, at the beginning of 1993) in addition to right censoring of observations at its end (here, at the end of 1999). The period estimates of cancer patient survival for the period of interest (here, for the 1993 through 1999 period) thus reflect the cumulative survival rates to be expected by newly diagnosed cancer patients, assuming that the conditional survival probabilities within defined time intervals after diagnosis observed in that period prevail. Obviously, these conditional survival probabilities refer to patients diagnosed in various calendar years. For example, in the period analysis for the 1993 through 1999 period, survival experience during the first year after diagnosis is provided by patients diagnosed between 1992 and 1999, survival experience in the second year after diagnosis is provided by patients diagnosed in 1991 through 1998, and so on, until survival experience in the 40th year after diagnosis, which is provided by patients diagnosed in 1953 through These conditional survival probabilities within single years are then multiplied to calculate cumulative survival rates. It has been shown by extensive empirical evaluation that estimates of long-term survival obtained by period analysis for a certain time period quite closely predict the long-term survival of patients diagnosed in that period (which can be obtained by traditional survival analysis only many years later). However, even the most recent period estimates may be somewhat too pessimistic with respect to the long-term prognosis to be expected by recently diagnosed patients in case of ongoing improvement in prognosis, albeit much less so than traditional cohort survival estimates [17-19]. At higher ages, decades after diagnosis, patients diagnosed with breast cancer before age 50 years obviously would be expected to have rapidly increasing mortality, even without having had breast cancer. Therefore, most survival rates presented in this article are relative rather than absolute (observed) survival rates. Relative survival rates reflect so-called net survival of patients with cancer. They can be interpreted as the expected survival experience of cancer patients in the hypothetical situation in which cancer is the only cause of death [20]. Relative survival rates are calculated as the ratio of absolute survival rates of cancer patients divided by the expected survival rates of a group of persons of the corresponding age and sex in the general population, which were obtained from calendar-year specific population life-tables (which include patients with cancer). Estimates of expected survival were derived according to Hakulinen s method [21]. SEs of survival rates were calculated according to Greenwood s method [22]. All analyses were performed with the SAS software package (SAS Institute, Cary, NC) using a publicly available macro for both cohort and period analysis, which is described in detail elsewhere [23]. RESULTS Overall, 18,578 patients diagnosed with breast cancer before age 50 years were included in the analysis. Median age at diagnosis was 44 years (interquartile range, 40 to 47 years). Numbers of patients still alive and under observation at various points of follow-up are listed in Table 1 for the various cohorts of patients for which survival curves are shown. In addition, the corresponding numbers for the 1993 through 1999 period are given. For that period, the numbers of patients under observation at 0, 10, 20, 30, and 40 years after diagnosis equal the corresponding numbers of the cohorts of patients diagnosed in 1993 through 1999, 1983 through 1989, 1973 through 1979, 1963 through 1969, and 1953 through 1959, respectively. The numbers of patients diagnosed with breast cancer before age 50 increased more than three-fold between 1953 through 1959 and 1993 through Although the numbers of patients under 433
3 Brenner and Hakulinen Table 1. Numbers of Patients Under Observation at Various Time Points During Long-Term Follow-Up Included in the Analysis Years After Diagnosis cohort 1, cohort 1, cohort 2,336 1,412 1, cohort 3,513 2, cohort 4,963 2,324 1, observation decrease with increasing length of follow-up, the numbers are sufficiently large to derive reasonably precise estimates throughout the 40 years of follow-up addressed in our analysis. Figures 1 and 2 show the absolute and relative cohort survival curves for patients diagnosed in 1953 through 1959, 1963 through 1969, 1973 through 1979, and 1983 through 1989 as well as the absolute and relative 40-year period survival curve for the 1993 through 1999 period, respectively. Obviously, the absolute survival rates rapidly decrease in the third and fourth decade after diagnosis, when the remaining patients are reaching higher ages (Fig 1). Nevertheless, the 1993 through 1999 period estimate of 40-year Fig 2. Cohort relative survival curves for patients diagnosed with breast cancer before age 50 years in 1953 through 1959, 1963 through 1969, 1973 through 1979, and 1983 through 1989 (- - -) and period relative survival curve for the 1993 through 1999 period ( ). Finnish Cancer Registry, 1953 to 1999 database. Fig 1. Cohort absolute survival curves for patients diagnosed with breast cancer before age 50 years in 1953 through 1959, 1963 through 1969, 1973 through 1979, and 1983 through 1989 (- - -) and period absolute survival curve for the 1993 through 1999 period ( ). Finnish Cancer Registry, 1953 to 1999 database. survival still is approximately 22%, compared with only approximately 13% estimated for the 1953 through 1959 cohort (Fig 1). Ten-year relative survival was only approximately 50% among patients diagnosed in 1953 through Relative survival further decreased to approximately 40%, 35%, and 30%, respectively, at 20, 30, and 40 years after diagnosis, which indicates that these patients continued to have an excess mortality rate compared with the general population during the entire 40-year follow-up interval. Long-term survival rates gradually improved for cohorts of patients diagnosed in later decades, and the 10-year relative survival rates almost reached 70% for the 1983 to 1989 cohort. The period survival curve for the 1993 through 1999 period suggests that prognosis has further improved in recent years. However, a pronounced continuous decline of the survival curve prevailed over the entire 40-year interval (Fig 2). Tumor spread at diagnosis was known for 93.6% of breast cancer patients. Among these, the majority were diagnosed with localized (53.4%) or regional breast cancer (40.9%). Figures 3 and 4 show 40-year relative survival curves for the 1953 through 1959 cohort and the 1993 through 1999 period among these two groups of patients. No separate curves are shown for patients with distant 434 JOURNAL OF CLINICAL ONCOLOGY
4 Prognosis of Young Patients With Breast Cancer Fig 3. Cohort relative survival curve for patients diagnosed with localized breast cancer before age 50 years in 1953 through 1959 (- - -) and corresponding period relative survival curve for the 1993 through 1999 period ( ). Finnish Cancer Registry, 1953 to 1999 database. Fig 4. Cohort relative survival curve for patients diagnosed with regional breast cancer before age 50 years in 1953 through 1959 (- - -) and corresponding period relative survival curve for the 1993 through 1999 period ( ). Finnish Cancer Registry, 1953 to 1999 database. metastases, because of their small numbers (5.1% overall) and because of the low numbers of long-term survivors in this group. As expected, relative survival rates were much worse for patients with metastases in regional lymph nodes than in patients with localized tumors, but relative survival curves were declining over the entire 40-year follow-up interval even for patients with localized cancer. This pattern was particularly evident in the 1993 through 1999 period survival curves, even though these were considerably higher than the 1953 through 1959 cohort survival curves. Overall, approximately 5% of patients had a second primary breast cancer during follow-up. To assess to what extent long-term survival rates are affected by second primary breast cancers, we performed additional analyses in which all observations were censored at the time of diagnosis of a second primary breast cancer. Although this increased relative survival rates to some extent (for example, for the 1993 through 1999 period, the 40-year relative survival rates of patients with localized and regional breast cancer were increased by approximately 5 and 3 percent units, respectively), considerable excess mortality persisted throughout four decades after diagnosis, even in the absence of second primary breast cancers. Table 2 provides a more direct comparison of 10-year relative survival rates within the four subsequent decades of follow-up. For the second, third, and fourth decade, these 10-year relative survival rates are conditional survival rates; in other words, they pertain to patients still alive at the beginning of the respective decade (in contrast to the survival rates shown in the figures that are unconditional, ie, pertaining to the total number of patients at diagnosis). Although 10-year relative survival strongly increased from approximately 50% during the first decade after diagnosis to much higher levels in the subsequent decades in the cohort of patients diagnosed in the period of 1953 through 1959, they remained less than 90% in each decade and even decreased to slightly more than 80% in the fourth decade. In the 1993 through 1999 period analysis, 10-year relative survival was considerably higher in the first decade after diagnosis than for the 1953 through 1959 cohort (71.5% v 48.9%), but similar estimates of 10-year relative survival between 80% and 90% for subsequent decades (with estimates close to 80% for the fourth decade) were obtained in both types of analysis. Among patients with localized breast cancer, the 1993 through 1999 period estimates of 10-year relative survival were quite similar (at levels between 80% and 90%) for all four decades of follow-up; that is, the excess mortality within the next 10 years of patients who had already survived 10, 20, or 30 years was essentially the same as in the first 10 years after diagnosis. Similar patterns were seen for 435
5 Brenner and Hakulinen Table 2. Ten-Year Relative Survival Within Four Decades After Diagnosis (conditional on being alive at the beginning of the decade) for the 1953 Through 1959 Cohort and 1993 Through 1999 Period Years After Diagnosis Relative Survival (%) SE Relative Survival (%) SE Relative Survival (%) SE Relative Survival (%) SE cohort Total Localized Regional period Total Localized Regional the 1953 through 1959 cohort estimates, with the exception of the first 10 years after diagnosis, when relative survival was less than 70%. For patients with regional tumor spread, 10-year relative survival rates increased from much lower levels in the first decade after diagnosis to levels of approximately 80% in the second and third decade after diagnosis, and they decreased to levels of approximately 65% again in the fourth decade after diagnosis. This pattern was seen in both the cohort analysis for the 1953 through 1959 cohort and the period analysis for the 1993 through 1999 period, although 10-year survival during the first 10 years was again considerably lower for the 1953 through 1959 cohort than for the 1993 through 1999 period. The similarity of the cohort and period estimates for the fourth decade is not surprising, given that they are derived from partly overlapping databases. Although the SEs of survival estimates increase from decade to decade during follow-up given the reduction of the number of patients at risk over time, each of the relative survival estimates is by more than two SEs lower than 100%, and most relative survival estimates are by more than four SEs lower than 100%, which indicates that the persistence of excess mortality compared with that of the general population of the same age is highly statistically significant for each of the four decades after diagnosis. DISCUSSION This analysis illustrates that prognosis of patients diagnosed with breast cancer before age 50 years has considerably improved during the past decades. Nevertheless, these patients continue to have increased mortality throughout at least 40 years after diagnosis; in other words, breast cancer diagnosed before the age of 50 years remains a chronic disease that affects prognosis of patients for decades. This applies even if breast cancer is diagnosed in a localized stage, in which case 10-year relative survival rates of between 80% and 90% are now observed for each of the first four decades after diagnosis (conditional on being alive at the beginning of the decade) and in the absence of the occurrence of a second primary breast cancer. For patients with regional tumor spread, excess mortality owing to breast cancer remains substantially higher, particularly during the first and the fourth decade after diagnosis. According to the latest estimates from period analysis, cumulative 40-year relative survival is now approximately 43% for all cancers combined, 57% for localized cancers, and 24% for cancers with regional tumor spread. To our knowledge, this is the largest systematic analysis of long-term survival perspectives of patients diagnosed with breast cancer before age 50 years ever reported, and it is the first one to use period analysis, a new method of survival analysis that allows for more up-to-date estimates of longterm survival perspectives than traditional methods of survival analysis [15-19]. The few previous studies addressing breast cancer survival for more than 20 years after diagnosis were much smaller in terms of numbers of patients, and most had included breast cancer patients at different ages, of whom only a minority were younger than 50 years at the time of diagnosis. Some of these studies had suggested that excess risk of death may cease 20 years after diagnosis [5-7]. By contrast, our results, which are consistent with results from a smaller study specifically addressing long-term perspectives of young breast cancer patients [3], clearly indicate persistence of excess risk for at least four decades among breast cancer patients who are diagnosed before age 50 years. Apart from the fact that very-long-term survival rates are of particular relevance for patients diagnosed at comparably young ages, there are also other reasons to specifically address long-term survival expectations for these patients. Numerous epidemiologic studies have suggested major differences in the etiology and clinical course according to age at diagnosis, and it would not be surprising to see major differences in long-term prognosis as well. In fact, most studies that focused on survival of breast cancer patients 436 JOURNAL OF CLINICAL ONCOLOGY
6 Prognosis of Young Patients With Breast Cancer within 5 to 20 years after diagnosis found prognosis to be better among patients diagnosed with breast cancer in their fifth decade of life than among both younger and older patients [24-27]. Interestingly, in a study from New Zealand, in which very-long-term survival of breast cancer patients at various ages was assessed, patients between 35 and 55 years of age also had the lowest excess mortality within the first 5 years after diagnosis. At the same time, in contrast with older patients, an excess mortality beyond 20 years after diagnosis was observed in these age groups [4]. These findings underline the need to look at very-long-term survival rates to get the full picture of prognosis among patients diagnosed with breast cancer at comparably young ages. In the interpretation of our analysis, the following limitations should be kept in mind. Despite the large overall number of patients involved, further stratification of verylong-term survival estimates by additional factors, such as certain age groups within the limited age range included in our study, was prohibitive because of sample size limitations. Our study also does not provide (and was not intended to provide) evidence regarding potential differences in very-long-term survival rates between patients younger than and older than 50 years, which need to be addressed in additional analyses. Furthermore, details regarding the causes of the excess deaths among patients could not be derived from this registry-based study, but they should be assessed in future work specifically addressing this issue, because their identification might be helpful for focusing long-term clinical surveillance. Our data suggest, however, that second primary breast cancers account for a relatively small proportion of long-term excess mortality. Even though the period method provides more up-todate survival statistics than traditional cohort analysis, it is still using patients diagnosed many years ago to estimate long-term survival. In particular, even the 1993 through 1999 period estimates of 40-year survival were based on estimates of conditional survival in the third and fourth decade after diagnosis of patients diagnosed before screening or modern forms of therapy were widely available (or recommended for women younger than 50 years). Hence, although the 1993 through 1999 period estimates of 40-year survival are much more optimistic and up-to-date than the most recent cohort estimates of 40-year survival, they are likely to underestimate to some extent the survival expectations of patients diagnosed with breast cancer in recent years. Notwithstanding the need to take this issue into account, our results of the period analysis for the 1993 through 1999 period have important clinical implications: according to currently observed survival rates (which are, as far as pertinent data are available, quite similar to those observed in other developed countries, including the United States [28]), breast cancer among patients younger than 50 years is a truly chronic disease, despite the major progress in survival rates in the past decades. For example, according to our latest data from the 1993 through 1999 period, patients with localized breast cancer, who had had their diagnosis made up to 30 years ago, still have the same excess mortality as newly diagnosed patients (Table 2). Nevertheless, our results should not be used to put an additional burden of anxiety on patients diagnosed with breast cancer at young ages. Rather, these results underline the need for state-of-the-art long-term care, as well as further research regarding measures to reduce the long-term excess mortality in this group of patients. Authors Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. REFERENCES 1. Parkin DM: Global cancer statistics in the year Lancet Oncol 2: , Sutherland CM, Mather FJ: Long-term survival and prognostic factors in patients with regional breast cancer (skin, muscle and/or chest wall attachment). Cancer 55: , Rutqvist LE, Wallgren A: Long-term survival of 458 young breast cancer patients. Cancer 55: , Hibberd AD, Horwood LJ, Wells JE: Long term prognosis of women with breast cancer in New Zealand: Study of survival to 30 years. BMJ 286: , Nab HW, Hop WCJ, Crommelin MA, et al: Changes in long term prognosis of breast cancer in a Dutch cancer registry. BMJ 309:83-86, Louwman WJ, Klokman WJ, Coebergh JWW: Excess mortality from breast cancer 20 years after diagnosis when life expectancy is normal. Br J Cancer 84: , Joensuu H, Toikkanen S: Cured of breast cancer? J Clin Oncol 13:62-69, Adami H-O, Malker B, Rutqvist L-E, et al: Temporal trends in breast cancer survival in Sweden: Significant improvement in 20 years. J Natl Cancer Inst 76: , Nab HW, Hop WCJ, Crommelin MA, et al: Improved prognosis of breast cancer since 1970 in south-eastern Netherlands. Br J Cancer 70: , Chu KC, Tarone RE, Kessler LG, et al: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88: , Edwards MJ, Gamel JW, Feuer EJ: Improvement in the prognosis of breast cancer from 1965 to J Clin Oncol 16: , Brenner H, Stegmaier C, Ziegler H: Recent improvement in survival of breast cancer patients in Saarland, Germany. Br J Cancer 78: , Teppo L, Pukkala E, Lehtonen M: Data quality and quality control of a population based cancer registry: Experience in Finland. Acta Oncol 33: , Dickman PW, Hakulinen T, Luostarinen T, et al: Survival of cancer patients in Finland Acta Oncol 38:1-103, 1999 (suppl 12) 15. Brenner H, Gefeller O: An alternative approach to monitoring cancer patient survival. Cancer 78: , Brenner H, Gefeller O: Deriving more upto-date estimates of long term patient survival. J Clin Epidemiol 50: , Brenner H, Hakulinen T: Up-to-date long term survival estimates of patients with cancer by period analysis. J Clin Oncol 20: , Brenner H, Hakulinen T: Very-long-term survival rates of patients with cancer. J Clin Oncol 20: , Brenner H, Söderman B, Hakulinen T: Use of period analysis for providing more up-to-date estimates of long-term survival rates: Empirical evaluation among 370, 000 cancer patients in Finland. Int J Epidemiol 31: ,
7 Brenner and Hakulinen 20. Ederer F, Axtell LM, Cutler SJ: The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 6: , Hakulinen T: Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 38: , Greenwood M: A Report on the Natural Duration of Cancer. London, United Kingdom, Ministry of Health, His Majesty s Stationery Office, Brenner H, Hakulinen T, Gefeller O: Computational realization of period analysis for monitoring cancer patient survival. Epidemiology 13: , Adami H-O, Malker B, Holmberg L, et al: The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315: , Sant M, Gatta G, Micheli A, et al: Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer 27: , Levi F, Randimbison L, La Vecchia C: Breast cancer survival in relation to sex and age. Oncology 49: , de la Rochefordiere A, Asselan B, Campana F, et al: Age as a prognostic factor in premenopausal breast cancer. Lancet 341: , Brenner H: Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 360: , JOURNAL OF CLINICAL ONCOLOGY
Published Ahead of Print on October 3, 2011 as 10.1200/JCO.2011.36.8902. J Clin Oncol 29. 2011 by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on October 3, 211 as 1.12/JCO.211.36.892 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.892 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Incidence
More informationFraction of normal remaining life span: a new method for expressing survival in cancer
Home Help Search/Archive Feedback Search Result BMJ 1997;314:1682 (7 June) Education and debate Fraction of normal remaining life span: a new method for expressing survival in cancer Jayant S Vaidya, surgical
More informationRelative survival an introduction and recent developments
Relative survival an introduction and recent developments Paul W. Dickman Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm, Sweden paul.dickman@ki.se 11 December 2008
More informationFinnish Cancer Registry Institute for Statistical and Epidemiological Cancer Research. Survival ratios of cancer patients by area in Finland
Survival ratios of cancer patients by area in Finland Pages 2 14 present the relative survival ratios for patients diagnosed in 2005 2012 and followed-up in 2010 2012 (see Methods p. 15) on different university
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationScreening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement
Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement Rebecca Ferrini, MD, Elizabeth Mannino, MD, Edith Ramsdell, MD and Linda Hill, MD, MPH Burden
More informationLa sopravvivenza dei tumori maligni nei confronti internazionali: anticipazione della diagnosi o modifica del decorso naturale della malattia?
La sopravvivenza dei tumori maligni nei confronti internazionali: anticipazione della diagnosi o modifica del decorso naturale della malattia? Paola Pisani Registro Tumori Infantili Piemonte Università
More informationchapter 5. Quality control at the population-based cancer registry
chapter 5. Quality control at the population-based cancer registry All cancer registries should be able to give some objective indication of the quality of the data that they have collected. The methods
More informationSection 8» Incidence, Mortality, Survival and Prevalence
Section 8» Incidence, Mortality, Survival and Prevalence 8.1. Description of Statistics Reported This section focuses on the regional distribution of cancer with data derived from the BC Cancer Registry
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationBreast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies
Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Richard Wender, MD Session code: www.worldcancercongress.org A Five Step Framework to Guide Screening
More informationCurrent Status and Problems of Breast Cancer Screening
Research and Reviews Current Status and Problems of Breast Cancer Screening JMAJ 52(1): 45 49, 2009 Noriaki OHUCHI,* 1,2 Akihiko SUZUKI,* 1,3 Yuu SAKURAI,* 1,4 Masaaki KAWAI,* 1 Yoko NARIKAWA,* 1 Hiroto
More informationEmerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden
596500SJP0010.1177/1403494815596500B. Järvholm and A. BurdorfAsbestos ban reduces mesothelioma incidence research-article2015 Scandinavian Journal of Public Health, 1 7 Original Article Emerging evidence
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationMeasures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSix Degrees of Separation No More: Using Data Linkages to Improve the Quality of Cancer Registry and Study Data
Six Degrees of Separation No More: Using Data Linkages to Improve the Quality of Cancer Registry and Study Data Prepared for the 138th Annual Meeting of the American Public Health Association Denver, CO
More informationHow To Decide If You Should Get A Mammogram
American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women
More informationEarly mortality rate (EMR) in Acute Myeloid Leukemia (AML)
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationSingapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013. National Registry of Diseases Office (NRDO)
Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013 National Registry of Diseases Office (NRDO) Released November 3, 2014 Acknowledgement This report was
More informationNumber. Source: Vital Records, M CDPH
Epidemiology of Cancer in Department of Public Health Revised April 212 Introduction The general public is very concerned about cancer in the community. Many residents believe that cancer rates are high
More informationStatistics fact sheet
Statistics fact sheet Fact sheet last updated January 2015 EXTERNAL VERSION Macmillan Cancer Support Page 1 of 10 Macmillan and statistics Statistics are important to Macmillan because they help us represent
More informationBasics and limitations of adjuvant online an internet based decision tool
Basics and limitations of adjuvant online an internet based decision tool J. Huober SAKK, Bern 31.10.2013 Univ.-Frauenklinik Ulm Integratives Tumorzentrum des Universitätsklinikums und der Medizinischen
More informationNational Life Tables, United Kingdom: 2012 2014
Statistical bulletin National Life Tables, United Kingdom: 2012 2014 Trends for the UK and constituent countries in the average number of years people will live beyond their current age measured by "period
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More information4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
More informationCancer in Ireland 2013: Annual report of the National Cancer Registry
Cancer in 2013: Annual report of the National Cancer Registry ABBREVIATIONS Acronyms 95% CI 95% confidence interval APC Annual percentage change ASR Age standardised rate (European standard population)
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationTable 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006
Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd
More informationCONTINUING MEDICAL EDUCATION
ANZ J. Surg. 2004; 74: 931 934 CONTINUING MEDICAL EDUCATION CONTINUING MEDICAL EDUCATION CANCER STATISTICS: EVERYTHING YOU WANTED TO KNOW ABOUT THE CANCER REGISTRY DATA BUT WERE TOO AFRAID TO ASK GRAHAM
More informationChapter 13. The hospital-based cancer registry
Chapter 13. The hospital-based cancer registry J.L. Young California Tumor Registry, 1812 14th Street, Suite 200, Sacramento, CA 95814, USA Introduction The purposes of a hospital-based cancer registry
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More informationChapter 2 History of MD Anderson s Tumor Registry
Chapter 2 History of MD Anderson s Tumor Registry Sarah H. Taylor The Tumor Registry Department at The University of Texas MD Anderson Cancer Center is responsible for a database that contains demographic
More informationAUSTRALIA AND NEW ZEALAND FACTSHEET
AUSTRALIA AND NEW ZEALAND FACTSHEET What is Stillbirth? In Australia and New Zealand, stillbirth is the death of a baby before or during birth, from the 20 th week of pregnancy onwards, or 400 grams birthweight.
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationQ&A on methodology on HIV estimates
Q&A on methodology on HIV estimates 09 Understanding the latest estimates of the 2008 Report on the global AIDS epidemic Part one: The data 1. What data do UNAIDS and WHO base their HIV prevalence estimates
More informationTrends in Prostate Cancer Mortality among Black Men and White Men in the United States
1507 Trends in Prostate Cancer Mortality among Black Men and White Men in the United States Kenneth C. Chu, Ph.D. 1 Robert E. Tarone, Ph.D. 2 Harold P. Freeman, M.D. 1 1 Center to Reduce Cancer Health
More informationTips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD
Tips for surviving the analysis of survival data Philip Twumasi-Ankrah, PhD Big picture In medical research and many other areas of research, we often confront continuous, ordinal or dichotomous outcomes
More informationMethodology Understanding the HIV estimates
UNAIDS July 2014 Methodology Understanding the HIV estimates Produced by the Strategic Information and Monitoring Division Notes on UNAIDS methodology Unless otherwise stated, findings in this report are
More informationMesothelioma mortality in Great Britain 1968-2009. Summary 2. Overall scale of disease including trends 3. Region 6. Occupation 7
Health and Safety Executive Mesothelioma Mesothelioma mortality in Great Britain 1968-2009 Contents Summary 2 Overall scale of disease including trends 3 Region 6 Occupation 7 Estimation of the future
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationThe current status of cancer care in Taiwan
The current status of cancer care in Taiwan Chien- Yuan Wu Director of Cancer Prevention and Control Division Health Promotion Administration Ministry of Health and Welfare, Taiwan Where is Taiwan? n Taiwan
More informationEffect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
More informationChapter 14 Cancer of the Cervix Uteri
Carol L. Kosary Introduction Despite the existence of effective screening through the use of Pap smears since the 195 s, there were 9,71 estimated cases of invasive cervical cancer and 3,7 deaths in 26
More informationTravel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
More informationBreast Cancer in Young Women: Quality of Life and Survivorship
Breast Cancer in Young Women: Quality of Life and Survivorship Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Breast Cancer in Young Women is
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationCancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?
Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance
More informationWeb portal for information on cancer epidemiology in the Czech Republic
Web portal for information on cancer epidemiology in the Czech Republic Dusek L. 1,2, Muzik J. 1, Kubasek M. 3, Koptikova J. 1, Brabec P. 1, Zaloudik J. 4, Vyzula R. 4 Abstract The aim of this article
More informationPSA Screening and the USPSTF Understanding the Controversy
PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationThe Risk of Losing Health Insurance Over a Decade: New Findings from Longitudinal Data. Executive Summary
The Risk of Losing Health Insurance Over a Decade: New Findings from Longitudinal Data Executive Summary It is often assumed that policies to make health insurance more affordable to the uninsured would
More informationANNEX 2: Assessment of the 7 points agreed by WATCH as meriting attention (cover paper, paragraph 9, bullet points) by Andy Darnton, HSE
ANNEX 2: Assessment of the 7 points agreed by WATCH as meriting attention (cover paper, paragraph 9, bullet points) by Andy Darnton, HSE The 7 issues to be addressed outlined in paragraph 9 of the cover
More informationChapter 15 Multiple myeloma
Chapter 15 Multiple myeloma Peter Adamson Summary In the UK and in the 199s, multiple myeloma accounted for around 1 in 8 diagnosed cases of cancer and 1 in 7 deaths from cancer. There was relatively little
More informationMissing data and net survival analysis Bernard Rachet
Workshop on Flexible Models for Longitudinal and Survival Data with Applications in Biostatistics Warwick, 27-29 July 2015 Missing data and net survival analysis Bernard Rachet General context Population-based,
More informationDisparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance
Disparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance Acknowledgements and Disclaimer The collection of cancer incidence data used in this
More informationThe American population is aging, and forecasts predict that by. The Natural History of Breast Carcinoma in the Elderly
1807 The Natural History of Breast Carcinoma in the Elderly Implications for Screening and Treatment Rachana Singh, M.D. Samuel Hellman, M.D. Ruth Heimann, M.D., Ph.D. Department of Radiation and Cellular
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationLecture 2 ESTIMATING THE SURVIVAL FUNCTION. One-sample nonparametric methods
Lecture 2 ESTIMATING THE SURVIVAL FUNCTION One-sample nonparametric methods There are commonly three methods for estimating a survivorship function S(t) = P (T > t) without resorting to parametric models:
More informationBreast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationGeneral and Abdominal Adiposity and Risk of Death in Europe
Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke General and Abdominal Adiposity and Risk of Death in Europe Tobias Pischon Department of Epidemiology German Institute of Human Nutrition Potsdam-Rehbruecke
More informationSocial inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)
Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationHow To Register Your Child For A Heart Defect Survey In Germany
Information for parents/legal guardians including declaration of consent to the study Information for parents/legal guardians Please read this information carefully. Your consulting physician will also
More information9 Expenditure on breast cancer
9 Expenditure on breast cancer Due to the large number of people diagnosed with breast cancer and the high burden of disease related to it, breast cancer is associated with substantial health-care costs.
More information2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
More informationNicole Kounalakis, MD
Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationHIP FRACTURES IN MEN WITH PROSTATE CANCER TREATED WITH ORCHIECTOMY
0022-5347/04/1726-2208/0 Vol. 172, 2208 2212, December 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000143930.73016.c6 HIP FRACTURES
More informationCancer in North Carolina 2013 Report
Cancer in North Carolina 2013 Report January 2014 Updated by Central Cancer Registry Cancer in North Carolina Purpose Cancer is the leading cause of death in North Carolina even though cancer mortality
More informationAnalysis of Population Cancer Risk Factors in National Information System SVOD
Analysis of Population Cancer Risk Factors in National Information System SVOD Mužík J. 1, Dušek L. 1,2, Pavliš P. 1, Koptíková J. 1, Žaloudík J. 3, Vyzula R. 3 Abstract Human risk assessment requires
More informationOriginally published as:
Originally published as: Reuss, A.M., Wiese-Posselt, M., Weißmann, B., Siedler, A., Zuschneid, I., An Der Heiden, M., Claus, H., Von Kries, R., Haas, W.H. Incidence rate of nontuberculous mycobacterial
More informationCHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:
More informationNo. prev. doc.: 8770/08 SAN 64 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008
COUNCIL OF THE EUROPEAN UNION Brussels, 22 May 2008 9636/08 SAN 87 NOTE from: Committee of Permanent Representatives (Part 1) to: Council No. prev. doc.: 8770/08 SAN 64 Subject: EMPLOYMENT, SOCIAL POLICY,
More informationBMJ 2014;348:g366 doi: 10.1136/bmj.g366 Page 1 of 10
BMJ 2014;348:g366 doi: 10.1136/bmj.g366 Page 1 of 10 Research Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening
More informationChapter 4. Planning a cancer registry
Chapter 4. Planning a cancer registry 0. M. Jensenl and S. Whelan2 Danish Cancer Registry, Danish Cancer Society, Rosenvaengets Hoveduej 35, PO Box 839, Copenhagen 21nternational Agency for Research on
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationSriplung H. Projection of Cancer Problems. Chapter IV CANCER PROBLEMS PROJECTION OF. CANCER IN THAILAND : Vol. IV. p. 79-Blue
Projection of Cancer Problems Sriplung H Chapter IV PROJECTION OF CANCER PROBLEMS 79 p. 79-Blue «à ß Projection of Cancer Problems Sriplung H CHAPTER IV PROJECTION OF CANCER PROBLEMS Hutcha Sriplung, M.D.
More informationThe recommendations made throughout this book are by the National Health and Medical Research Council (NHMRC).
INTRODUCTION This book has been prepared for people with bowel cancer, their families and friends. The first section is for people with bowel cancer, and is intended to help you understand what bowel cancer
More information4 Good Tips Advocacy and Campaigns to Promote Cancer Care Li-Ying Chiu. Research and Development Specialist HOPE Foundation for Cancer Care
4 Good Tips Advocacy and Campaigns to Promote Cancer Care Li-Ying Chiu Research and Development Specialist HOPE Foundation for Cancer Care 1 Taiwan Area 36,000 km² Population : 23 million Coverage of NHI
More informationLow-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
More informationColorectal Cancer Screening Behaviors among American Indians in the Midwest
JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 4, Number 2, Fall 2010, pp. 35 40 2010 Center for Health Disparities Research School of Community Health Sciences University
More informationNIH Public Access Author Manuscript Genet Med. Author manuscript; available in PMC 2009 August 13.
NIH Public Access Author Manuscript Published in final edited form as: Genet Med. 2006 September ; 8(9): 571 575. doi:10.1097/01.gim.0000237867.34011.12. Population-based study of the prevalence of family
More informationCOST OF SKIN CANCER IN ENGLAND MORRIS, S., COX, B., AND BOSANQUET, N.
ISSN 1744-6783 COST OF SKIN CANCER IN ENGLAND MORRIS, S., COX, B., AND BOSANQUET, N. Tanaka Business School Discussion Papers: TBS/DP05/39 London: Tanaka Business School, 2005 1 Cost of skin cancer in
More informationOncology Nursing Society Annual Progress Report: 2008 Formula Grant
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for
More informationCritical Appraisal of Article on Therapy
Critical Appraisal of Article on Therapy What question did the study ask? Guide Are the results Valid 1. Was the assignment of patients to treatments randomized? And was the randomization list concealed?
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationIV. DEMOGRAPHIC PROFILE OF THE OLDER POPULATION
World Population Ageing 195-25 IV. DEMOGRAPHIC PROFILE OF THE OLDER POPULATION A. AGE COMPOSITION Older populations themselves are ageing A notable aspect of the global ageing process is the progressive
More informationUICC World Cancer Congress. Cancer Staging and Quality of Care
UICC World Cancer Congress August 27 30, 2012, Montreal CANCER STAGE: A neglected cornerstone of Cancer Control Cancer Staging and Quality of Care Christian Wittekind Institut für Pathologie UKL 1 Agenda!
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en Cancer
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationCancer Prognostic Resources: A Systematic Review and Central Repository of Webbased Cancer Prognostic Calculators
Cancer Prognostic Resources: A Systematic Review and Central Repository of Webbased Cancer Prognostic Calculators 20 th Annual HMORN Conference Phoenix, AZ April 3, 2014 Presenter: Michelle Henton, MA
More information